256 related articles for article (PubMed ID: 28191850)
1. Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
Perez C; Li J; Parlati F; Rouffet M; Ma Y; Mackinnon AL; Chou TF; Deshaies RJ; Cohen SM
J Med Chem; 2017 Feb; 60(4):1343-1361. PubMed ID: 28191850
[TBL] [Abstract][Full Text] [Related]
2. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
Li J; Yakushi T; Parlati F; Mackinnon AL; Perez C; Ma Y; Carter KP; Colayco S; Magnuson G; Brown B; Nguyen K; Vasile S; Suyama E; Smith LH; Sergienko E; Pinkerton AB; Chung TDY; Palmer AE; Pass I; Hess S; Cohen SM; Deshaies RJ
Nat Chem Biol; 2017 May; 13(5):486-493. PubMed ID: 28244987
[TBL] [Abstract][Full Text] [Related]
3. Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11.
Li J; Zhang Y; Da Silva Sil Dos Santos B; Wang F; Ma Y; Perez C; Yang Y; Peng J; Cohen SM; Chou TF; Hilton ST; Deshaies RJ
Cell Chem Biol; 2018 Nov; 25(11):1350-1358.e9. PubMed ID: 30146242
[TBL] [Abstract][Full Text] [Related]
4. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
5. Substituted quinolines as noncovalent proteasome inhibitors.
McDaniel TJ; Lansdell TA; Dissanayake AA; Azevedo LM; Claes J; Odom AL; Tepe JJ
Bioorg Med Chem; 2016 Jun; 24(11):2441-2450. PubMed ID: 27112450
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Hu S; Jin Y; Liu Y; Ljungman M; Neamati N
Eur J Med Chem; 2018 Oct; 158():884-895. PubMed ID: 30253345
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Wang H; Yang Q; Dou QP; Yang H
Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010
[TBL] [Abstract][Full Text] [Related]
9. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
Pundir S; Vu HY; Solomon VR; McClure R; Lee H
Cancer Res; 2015 Oct; 75(19):4164-75. PubMed ID: 26238784
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
12. Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Tsukamoto S
Chem Pharm Bull (Tokyo); 2016; 64(2):112-8. PubMed ID: 26833439
[TBL] [Abstract][Full Text] [Related]
13. The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells.
Yerlikaya A; Kanbur E
Curr Drug Targets; 2020; 21(13):1313-1325. PubMed ID: 32448101
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
15. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
16. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
17. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
18. A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
Trader DJ; Simanski S; Kodadek T
J Am Chem Soc; 2015 May; 137(19):6312-9. PubMed ID: 25914958
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
Moon S; Muniyappan S; Lee SB; Lee BH
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207520
[TBL] [Abstract][Full Text] [Related]
20. Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment.
Wang H; Wu Z; Cao Y; Gao L; Shao J; Zhao Y; Zhang J; Zhou Y; Wei G; Li J; Zhu H
Bioorg Chem; 2023 Sep; 138():106626. PubMed ID: 37295239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
